Effects of bortezomib combined with dexamethasone and thalidomide on bone metabolism regulating factors, immune function and renal function in patients with multiple myeloma complicated with renal insufficiency

摘要

Objective: To investigate the effects of bortezomib combined with dexamethasone and thalidomide on the levels of bone metabolism regulating factors, immune function and renal function in patients with multiple myeloma complicated with renal insufficiency. Methods:According to the random data table, a total of 90 patients with multiple myeloma complicated with renal insufficiency were divided into the control group (n=45) and observation group (n=45), patients in the two groups were treated with diuretic, hydration and other symptomatic and supportive treatment, on this basis, the control group were treated with cyclophosphamide, dexamethasone and thalidomide regimen treatment, and the patients in the observation group were given bortezomib, dexamethasone and thalidomide regimen treatment, before treatment (before chemotherapy) and after treatment (3 cycles of chemotherapy) the levels of bone metabolic regulating factors, immune function and renal function between the two groups were compared. Results: The difference of the levels of RANKL, TRACP-5b, CD3+, CD4+, CD8+, CD4+/CD8+, SCr, BUN in the two groups before treatment were not significant. Compared with the control groups levels after treatment, the levels of RANKL, TRACP-5b, CD8+, SCr and BUN in the observation group were significantly decreased, and the levels of CD3+, CD4+and CD4+/CD8+ were significantly increased, the difference was statistically significant. Conclusion: Bortezomib in combination with dexamethasone and thalidomide in treatment of multiple myeloma with renal insufficiency, can effectively reduce the level of bone metabolism in regulating factor, improve immune function and renal function, it has an important clinical value.